The study also discovered that perturbation of the antidiabetic drug target SLC5A2 was significantly associated with an increased risk of basal cell carcinoma (for SLC5A2 perturbation equivalent to a 6.75 mmol/mol decrement in HbA1c: OR: 2.004, 95% CI: 1.270–3.161, p = 0.0027). Here, SLC5A2 is linked to basal cell carcinoma.